Abstract 3558: A pilot clinical study of limonene in women with early stage breast cancer: Effects of short-term treatment on tissue limonene disposition and serum markers

Author(s):  
Jessica A. Miller ◽  
Julie E. Lang ◽  
Chiu-Hsieh Hsu ◽  
Michele Ley ◽  
Amy L. Waer ◽  
...  
2004 ◽  
Vol 49 (1) ◽  
pp. 59-65 ◽  
Author(s):  
Maryam R. Sartippour ◽  
Jian Yu Rao ◽  
Sophia Apple ◽  
Debbie Wu ◽  
Susanne Henning ◽  
...  

2020 ◽  
Vol 245 (17) ◽  
pp. 1552-1559
Author(s):  
Tsui-Ting Ching ◽  
Yen-Chieh Chen ◽  
Guang Li ◽  
Jianfeng Liu ◽  
X Z Shawn Xu ◽  
...  

Age-related mobility decline is often associated with negative physical and psychological outcomes, such as frailty, in the elderly population. In C. elegans, during the early stage of the aging process, a progressive deficit of synaptic exocytosis in the motor neurons results in a functional decline at the neuromuscular junctions, which eventually leads to degeneration of both neurons and muscles. This age-dependent functional decline can be ameliorated by pharmacological interventions, such as arecoline, a muscarinic AChR agonist known to promote synaptic exocytosis at the neuromuscular junctions. In this study, we found that a short-term treatment of arecoline during the early stage of aging, when the NMJ functional decline begins, not only slows muscle tissue aging, but also extends lifespan in C. elegans. We have also demonstrated that arecoline acts on the GAR-2/PLCβ pathway in the motor neurons to increases longevity. Together, our findings suggest that synaptic transmission in aging motor neurons may serve as a potential target for pharmacological interventions to promote both health span and lifespan, when applied at the early stage aging. Impact statement The functional decline of motor activity is a common feature in almost all aging animals that leads to frailty, loss of independence, injury, and even death in the elderly population. Thus, understanding the molecular mechanism that drives the initial stage of this functional decline and developing strategies to increase human healthspan and even lifespan by targeting this process would be of great interests to the field. In this study, we found that by precisely targeting the motor neurons to potentiate its synaptic releases either genetically or pharmacologically, we can not only delay the functional aging at NMJs but also slow the rate of aging at the organismal level. Most importantly, we have demonstrated that a critical window of time, that is the early stage of NMJs functional decline, is required for the beneficial effects. A short-term treatment within this time period is sufficient to extend the animals’ lifespan.


2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e11537-e11537
Author(s):  
Hilbrahim Petekkaya ◽  
Sercan Aksoy ◽  
Gizem Gecmez ◽  
Emre Kulahcioglu ◽  
Alexis K. Okoh ◽  
...  

e11537 Background: In a few number of studies a possible relationship between inflammatory markers and the prognosis, chemotherapy response and survival in breast cancer has been reported. The aim of this study is to point out the place of serum markers as a prognostic factor in early stage breast cancer. Methods: This study was conducted in Hacettepe University Cancer Institute. Patients operated and stage IA to III C for breast cancer between December 2009 and June 2012 were included the study. Before the any adjuvant therapy inflammation markers were studied. Results: A total of 704 patients were included in the study. The median age of the patients was 50 (25-92). 42,8% of the patients were premenopausal and 48,2% postmenopausal. The median follow up period for the whole study group was 22 months (3-287). We studied the CRP, erythrocyte sedimentation rate, B2 microglobulin, LDH, albumin, and ferritin studied and values for each marker were grouped as high and normal. There was no statistically significant difference in disease free survival and overall survival for each marker who had high and normal levels. Conclusions: We did not found any inflammatory markers as a prognostic value. However our follow up time is short and we should be wait for more mature data.


Author(s):  
Arunkumar Arumugam ◽  
Maricarmen Stout ◽  
Cathy Tsin ◽  
Amar Bhat ◽  
Taylor Yong ◽  
...  

2020 ◽  
Vol 152 ◽  
pp. S499-S500
Author(s):  
N. Mészáros ◽  
V. Smanykó ◽  
T. Major ◽  
G. Stelczer ◽  
L. Jánváry ◽  
...  

2021 ◽  
pp. 203-209
Author(s):  
Nitin T Telang ◽  
Hareesh B Nair ◽  
George YC Wong

Background: Tabebuia avellanedae (TA) is a tree that is indigenous to the Amazon rainforest. The experiments in the present study were designed to examine the inhibitory effects of TA, and to identify mechanistic targets for its efficacy in the estrogen-α receptor (ER-α), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2) negative MDA-MB-231 model for triple negative breast cancer (TNBC). Methods: Non-fractionated aqueous extract from the inner bark of TA was used in the experiments. Anchorage dependent growth, anchorage independent (AI) colony formation, cell cycle progression, and expressions of relevant regulatory proteins represented quantitative end points. Results: Long-term treatment for 21 days with the maximum cytostatic concentration of 2.5% TA resulted in a 90% inhibition (P=0.014) in AI colony number. Short-term treatment for 2 days with 1.0% TA (IC50) resulted in about a 1.3 fold increase (P=0.014) in G1: S+G2/M ratio, about a 1.48 fold increase (P=0.010) in the sub G0 (apoptotic) cells and about a 3.2 fold increase (P=0.014) in the pro-apoptotic caspase 3/7 activity. Mechanistically, the short-term treatment with 2.5% TA decreased Cyclin D1 expression by about 83.3%, and pRB expression by about 73.3%. Conclusion: TNBC represents an aggressive cancer notable for its resistance to conventional and targeted therapy. Non-toxic natural substances may represent testable alternatives. This study identifies potential mechanistic leads for TA as a novel naturally occurring testable alternative for secondary prevention/therapy of TNBC, and validates a novel mechanistic approach to evaluate efficacious non-toxic phytochemicals and herbs as testable alternatives against therapy resistant breast cancer.


The Breast ◽  
2020 ◽  
Vol 52 ◽  
pp. 23-32 ◽  
Author(s):  
Antonio Di Meglio ◽  
Stefan Michiels ◽  
Lee W. Jones ◽  
Mayssam El-Mouhebb ◽  
Arlindo R. Ferreira ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document